News | January 06, 2026
Wegovy pill marks first GLP-1 weight-loss medicine in oral form
The approval introduces a needle-free alternative to injectable GLP-1 therapies
The approval introduces a needle-free alternative to injectable GLP-1 therapies
Abbott’s latest innovation promises to shift diabetes management from reactive to proactive
The approval is supported by data from three pivotal clinical trials
Elanco expects Befrena to launch in the US in the first half of 2026
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
The surgical team used LD Flap Reconstruction, a specialised technique that rebuilt elbow strength and movement
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
Afrezza comes in single-use cartridges, delivered via a simple inhaler device. Users select the appropriate cartridge, load it, inhale the insulin, and remove the cartridge
The opening of our 1000th pharmacy in Karnataka marks an important step
Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial
Subscribe To Our Newsletter & Stay Updated
